{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:37:54Z","timestamp":1793025474594,"version":"4.5.0"},"reference-count":161,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA293210"],"award-info":[{"award-number":["R01CA293210"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA242158"],"award-info":[{"award-number":["R01CA242158"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013019","name":"Rutgers Robert Wood Johnson Medical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.yexmp.2026.105079","type":"journal-article","created":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:42:29Z","timestamp":1790779349000},"page":"105079","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Hunter syndrome (mucopolysaccharidosis type II): Molecular mechanisms, CNS biomarkers, and emerging therapeutic strategies"],"prefix":"10.1016","volume":"148","author":[{"given":"Amelia Michelle Sojung","family":"Moon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung-Goo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euiyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Abdur","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkyu","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong Kun","family":"Cheon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Hyeon","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2026.105079_bb0005","series-title":"Genotype-Phenotype Spectrum of 130 Unrelated Indian Families with Mucopolysaccharidosis Type II","author":"Agrawal","year":"2022"},{"key":"10.1016\/j.yexmp.2026.105079_bb0010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjno-2021-000143","article-title":"Correlation between CSF and blood neurofilament light chain protein: a systematic review and meta-analysis","volume":"3","author":"Alagaratnam","year":"2021","journal-title":"BMJ Neurol. Open"},{"key":"10.1016\/j.yexmp.2026.105079_bb0015","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/pd.2786","article-title":"Preventing mucopolysaccharidosis type II (Hunter syndrome): PGD and establishing a Hunter (46, XX) stem cell line","volume":"31","author":"Altarescu","year":"2011","journal-title":"Prenat. Diagn."},{"key":"10.1016\/j.yexmp.2026.105079_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ajmg.1320160111","article-title":"Carrier detection in Hunter syndrome","volume":"16","author":"Archer","year":"1983","journal-title":"Am. J. Med. Genet."},{"key":"10.1016\/j.yexmp.2026.105079_bb0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.145445","article-title":"Iduronate-2-sulfatase transport vehicle rescues behavioral and skeletal phenotypes in a mouse model of Hunter syndrome","volume":"6","author":"Arguello","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.yexmp.2026.105079_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109055","article-title":"A link between baseline neurofilament light chain and primary substrate accumulation in cerebrospinal fluid, and clinical outcomes in patients with MPS II from a phase 2\/3 clinical trial and extension study of intrathecal idursulfase","volume":"144","author":"Argueta","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s11011-017-0110-5","article-title":"Aversive and non-aversive memory impairment in the mucopolysaccharidosis II mouse model","volume":"33","author":"Azambuja","year":"2018","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0040","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1007\/s11011-020-00592-5","article-title":"Evidence for inflammasome activation in the brain of mucopolysaccharidosis type II mice","volume":"35","author":"Azambuja","year":"2020","journal-title":"Metab. Brain Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0045","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1038\/s41598-023-37138-5","article-title":"A novel CRISPR\/Cas9-based iduronate-2-sulfatase (IDS) knockout human neuronal cell line reveals earliest pathological changes","volume":"13","author":"Badenetti","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0050","doi-asserted-by":"crossref","DOI":"10.3390\/genes15030342","article-title":"Optical genome mapping as a potential routine clinical diagnostic method","volume":"15","author":"Barseghyan","year":"2024","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.yexmp.2026.105079_bb0055","first-page":"62","article-title":"Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: a 7 years follow-up","volume":"12","author":"Barth","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0060","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s10545-012-9555-1","article-title":"Respiratory and sleep disorders in mucopolysaccharidosis","volume":"36","author":"Berger","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155188","article-title":"Characterization of fluid biomarkers reveals lysosome dysfunction and neurodegeneration in neuronopathic MPS II patients","volume":"21","author":"Bhalla","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2026.105079_bb0070","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ymthe.2017.03.025","article-title":"Hematopoietic stem cell gene therapy for storage disease: current and new indications","volume":"25","author":"Biffi","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0075","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000472302","article-title":"Presence of an IDS-related locus (IDS2) in Xq28 complicates the mutational analysis of Hunter syndrome","volume":"3","author":"Bondeson","year":"1995","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.yexmp.2026.105079_bb0080","series-title":"Inversion of the IDS Gene Resulting from Recombination with IDS-Related Sequences Is a Common Cause of the Hunter Syndrome","author":"Bondeson","year":"1995"},{"key":"10.1016\/j.yexmp.2026.105079_bb0085","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1007\/s10545-011-9359-8","article-title":"Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management","volume":"34","author":"Braunlin","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0090","series-title":"Homologous Nonallelic Recombinations between the Iduronate-Sulfatase Gene and Pseudogene Cause Various Intragenic Deletions and Inversions in Patients with Mucopolysaccharidosis Type II","author":"Bunge","year":"1998"},{"issue":"3","key":"10.1016\/j.yexmp.2026.105079_bib787","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/ijns6030073","article-title":"Newborn Screening for Mucopolysaccharidosis Type II in Illinois: An Update","volume":"6","author":"Burton","year":"2020","journal-title":"Int J. Neonatal. Screen"},{"key":"10.1016\/j.yexmp.2026.105079_bb0095","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s00431-012-1703-y","article-title":"Diagnosing Hunter syndrome in pediatric practice: practical considerations and common pitfalls","volume":"171","author":"Burton","year":"2012","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0100","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/s41419-024-06692-9","article-title":"Mature neurons from iPSCs unveil neurodegeneration-related pathways in mucopolysaccharidosis type II: GSK-3beta inhibition for therapeutic potential","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0105","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23179979","article-title":"Updated confirmatory diagnosis for Mucopolysaccharidoses in Taiwanese infants and the application of gene variants","volume":"23","author":"Chuang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105079_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.gim.2026.102596","article-title":"Nationwide newborn screening for mucopolysaccharidoses in Taiwan: impact, early diagnosis, and clinical advances over the past decade","volume":"28","author":"Chuang","year":"2026","journal-title":"Genet. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/jimd.12637","article-title":"Liver directed adeno-associated viral vectors to treat metabolic disease","volume":"47","author":"Chuecos","year":"2024","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0120","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ymgme.2012.05.003","article-title":"Biomarkers for the mucopolysaccharidoses: discovery and clinical utility","volume":"106","author":"Clarke","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0130","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21041258","article-title":"Mucopolysaccharidosis type II: one hundred years of research, diagnosis, and treatment","volume":"21","author":"D\u2019Avanzo","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"Suppl. 3","key":"10.1016\/j.yexmp.2026.105079_bb0135","doi-asserted-by":"crossref","first-page":"S395","DOI":"10.1007\/s10545-010-9197-0","article-title":"Quantitative in vivo brain magnetic resonance spectroscopic monitoring of neurological involvement in mucopolysaccharidosis type II (Hunter syndrome)","volume":"33","author":"Davison","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22179200","article-title":"Gene therapy for neuronopathic Mucopolysaccharidoses: state of the art","volume":"22","author":"de Castro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2026.105079_bb0145","series-title":"Heparan Sulfate and Dermatan Sulfate Derived Disaccharides Are Sensitive Markers for Newborn Screening for Mucopolysaccharidoses Types I, II and III","author":"de Ruijter","year":"2012"},{"key":"10.1016\/j.yexmp.2026.105079_bb0150","series-title":"Inflammation and Lipoperoxidation in Mucopolysaccharidoses Type II Patients at Diagnosis and Post-Hematopoietic Stem Cell Transplantation","author":"Delgado","year":"2024"},{"key":"10.1016\/j.yexmp.2026.105079_bb0155","doi-asserted-by":"crossref","first-page":"15786","DOI":"10.1038\/ncomms15786","article-title":"Insights into Hunter syndrome from the structure of iduronate-2-sulfatase","volume":"8","author":"Demydchuk","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.yexmp.2026.105079_bb0160","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s44222-025-00277-7","article-title":"Extracellular vesicles for the delivery of gene therapy","volume":"3","author":"Di Ianni","year":"2025","journal-title":"Nat. Rev. Bioeng."},{"key":"10.1016\/j.yexmp.2026.105079_bb0165","article-title":"The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome","volume":"22","author":"Eisengart","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0170","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.3174\/ajnr.A2032","article-title":"Correlation of automated volumetric analysis of brain MR imaging with cognitive impairment in a natural history study of mucopolysaccharidosis II","volume":"31","author":"Fan","year":"2010","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0180","doi-asserted-by":"crossref","DOI":"10.21037\/jlpm-24-33","article-title":"Determination of pediatric and adult reference intervals for neurofilament light chain (NfL) in blood and a comparison to other recent studies","volume":"9","author":"Figdore","year":"2024","journal-title":"J. Lab. Precis. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0185","series-title":"Oxidative Stress in Patients with Mucopolysaccharidosis Type II before and during Enzyme Replacement Therapy","author":"Filippon","year":"2011"},{"key":"10.1016\/j.yexmp.2026.105079_bb0190","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","article-title":"Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts","volume":"162","author":"Fratantoni","year":"1968","journal-title":"Science"},{"key":"10.1016\/j.yexmp.2026.105079_bb0195","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1651-2227.2002.tb03116.x","article-title":"Mucopolysaccharidosis type II\u2013genotype\/phenotype aspects","volume":"91","author":"Froissart","year":"2002","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0200","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1651-2227.2007.00213.x","article-title":"Mucopolysaccharidosis type II: an update on mutation spectrum","volume":"96","author":"Froissart","year":"2007","journal-title":"Acta Paediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0205","article-title":"Biomarkers in patients with mucopolysaccharidosis type II and IV","volume":"19","author":"Fujitsuka","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0210","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbrc.2023.04.093","article-title":"Contribution of vesicle trafficking dysregulation to the pathomechanism of mucopolysaccharidosis","volume":"665","author":"Gaffke","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.yexmp.2026.105079_bib781","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1007\/s10545-007-0641-8","article-title":"The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome)","volume":"30","author":"Garcia","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0215","article-title":"AAV engineering for improving tropism to the central nervous system","volume":"12","author":"Ghauri","year":"2023","journal-title":"Biol.-Basel"},{"key":"10.1016\/j.yexmp.2026.105079_bb0220","series-title":"ICIEM 2025, Kyoto, Japan","article-title":"CAMPSIITE\u00ae Phase I\/II\/III: Interim clinical update of clemidsogene lanparvovec (RGX-121), an investigational gene therapy for treatment of neuronopathic mucopolysaccharidosis type II (MPS II)","author":"Giugliani","year":"2025"},{"key":"10.1016\/j.yexmp.2026.105079_bb0225","first-page":"2","article-title":"Evaluation of impact of anti-idursulfase antibodies during long-term idursulfase enzyme replacement therapy in mucopolysaccharidosis II patients","volume":"12","author":"Giugliani","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222010938","article-title":"Enzyme replacement therapy with pabinafusp alfa for neuronopathic mucopolysaccharidosis II: an integrated analysis of preclinical and clinical data","volume":"22","author":"Giugliani","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2026.105079_bb0235","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1186\/s13023-024-03463-9","article-title":"Heparan sulfate in cerebrospinal fluid as a biomarker to assess disease severity and for treatment monitoring in patients with Mucopolysaccharidosis type II: a position statement","volume":"19","author":"Giugliani","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0172435","article-title":"Identification of age-dependent motor and neuropsychological behavioural abnormalities in a mouse model of mucopolysaccharidosis type II","volume":"12","author":"Gleitz","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2026.105079_bb0245","article-title":"Timing is everything: clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair","volume":"30","author":"Grant","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0250","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jpeds.2008.11.041","article-title":"Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years","volume":"154","author":"Guffon","year":"2009","journal-title":"J. Pediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0255","series-title":"Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study","author":"Guill\u00e9n-Navarro","year":"2013"},{"key":"10.1016\/j.yexmp.2026.105079_bb0260","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1016\/j.ymthe.2022.10.010","article-title":"First-in-human in vivo genome editing via AAV-zinc-finger nucleases for mucopolysaccharidosis I\/II and hemophilia B","volume":"30","author":"Harmatz","year":"2022","journal-title":"Mol. Ther."},{"issue":"439","key":"10.1016\/j.yexmp.2026.105079_bib783","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1651-2227.2002.tb03117.x","article-title":"Animal models for mucopolysaccharidoses and their clinical relevance","volume":"91","author":"Haskins","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"10.1016\/j.yexmp.2026.105079_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107632","article-title":"Endogenous, non-reducing end glycosaminoglycan biomarkers are superior to internal disaccharide glycosaminoglycan biomarkers for newborn screening of mucopolysaccharidoses and GM1 gangliosidosis","volume":"140","author":"Herbst","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0270","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1089\/hum.2016.101","article-title":"Delivery of an adeno-associated virus vector into cerebrospinal fluid attenuates central nervous system disease in mucopolysaccharidosis type II mice","volume":"27","author":"Hinderer","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0275","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1089\/hum.2016.087","article-title":"Adeno-associated virus-based gene therapy for CNS diseases","volume":"27","author":"Hocquemiller","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2019.101451","article-title":"Generation of an induced pluripotent stem cell line (TRNDi008-A) from a Hunter syndrome patient carrying a hemizygous 208insC mutation in the IDS gene","volume":"37","author":"Hong","year":"2019","journal-title":"Stem Cell Res."},{"issue":"7","key":"10.1016\/j.yexmp.2026.105079_bib786","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1001\/jamapediatrics.2018.0263","article-title":"Incidence of 4 Lysosomal Storage Disorders From 4 Years of Newborn Screening","volume":"172","author":"Hopkins","year":"2018","journal-title":"JAMA Pediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0285","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymgme.2017.12.428","article-title":"Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II","volume":"123","author":"Hoshina","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bib788","series-title":"Presented at: 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)","article-title":"Generation of a novel capsid engineering platform enhances CNS and muscle tropism of AAV vectors while reducing tropism to the liver","author":"Iizuka","year":"2025"},{"key":"10.1016\/j.yexmp.2026.105079_bb0290","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s40272-024-00627-9","article-title":"Advances in immune tolerance induction in enzyme replacement therapy","volume":"26","author":"Inci","year":"2024","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.yexmp.2026.105079_bb0295","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12951-024-02634-x","article-title":"Exosome for mRNA delivery: strategies and therapeutic applications","volume":"22","author":"Iqbal","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0300","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbadis.2016.05.021","article-title":"Oxidative and nitrative stress and pro-inflammatory cytokines in mucopolysaccharidosis type II patients: effect of long-term enzyme replacement therapy and relation with glycosaminoglycan accumulation","volume":"1862","author":"Jacques","year":"2016","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.yexmp.2026.105079_bb0305","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s10545-009-1119-7","article-title":"Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS)","volume":"32","author":"Jones","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0310","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajmg.c.31915","article-title":"Genotype-phenotype studies in a large cohort of Brazilian patients with Hunter syndrome","volume":"187","author":"Josahkian","year":"2021","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"issue":"1","key":"10.1016\/j.yexmp.2026.105079_bib782","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s10059-010-0083-2","article-title":"Characterization of a novel mucopolysaccharidosis type II mouse model and recombinant AAV2\/8 vector-mediated gene therapy","volume":"30","author":"Jung","year":"2010","journal-title":"Mol. Cells"},{"key":"10.1016\/j.yexmp.2026.105079_bb0315","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12808","article-title":"Natural history of valve disease in patients with mucopolysaccharidosis II and the impact of enzyme replacement therapy","volume":"48","author":"Kampmann","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0320","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0325","series-title":"Skewed X-Chromosome Inactivation in a Korean Girl with Severe Mucopolysaccharidosis Type II","author":"Kim","year":"2022"},{"key":"10.1016\/j.yexmp.2026.105079_bb0330","article-title":"Lysosome-mitochondrial crosstalk in cellular stress and disease","volume":"14","author":"Kiraly","year":"2025","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.yexmp.2026.105079_bb0335","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.yexcr.2019.04.021","article-title":"Modelling the neuropathology of lysosomal storage disorders through disease-specific human induced pluripotent stem cells","volume":"380","author":"Kobol\u00e1k","year":"2019","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.yexmp.2026.105079_bb0340","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ymgme.2016.12.010","article-title":"Glycosaminoglycan levels in dried blood spots of patients with mucopolysaccharidoses and mucolipidoses","volume":"120","author":"Kubaski","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0345","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.bbmt.2017.06.020","article-title":"Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II","volume":"23","author":"Kubaski","year":"2017","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.yexmp.2026.105079_bib784","article-title":"Diagnosis of Mucopolysaccharidoses","author":"Kubaski","year":"2020","journal-title":"Diagnostics (Basel) 10(3)"},{"key":"10.1016\/j.yexmp.2026.105079_bb0350","series-title":"A North Carolina Newborn Screening Pilot for Mucopolysaccharidosis II: Evaluating Endogenous Nonreducing End Glycosaminoglycan Analysis and IDS Sequencing as Higher-Tier Testing Options","author":"Kucera","year":"2026"},{"issue":"9","key":"10.1016\/j.yexmp.2026.105079_bib785","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0138622","article-title":"A Multiplex Assay for the Diagnosis of Mucopolysaccharidoses and Mucolipidoses","volume":"10","author":"Langereis","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.yexmp.2026.105079_bb0360","article-title":"Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: an analysis from the Hunter Outcome Survey","volume":"37","author":"Lau","year":"2023","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0365","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1038\/nchembio.766","article-title":"Disease-specific non-reducing end carbohydrate biomarkers for mucopolysaccharidoses","volume":"8","author":"Lawrence","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0370","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24010477","article-title":"Mucopolysaccharidoses: cellular consequences of glycosaminoglycans accumulation and potential targets","volume":"24","author":"Leal","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2026.105079_bb0375","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3345\/kjp.2012.55.3.88","article-title":"A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients","volume":"55","author":"Lee","year":"2012","journal-title":"Korean J. Pediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.scr.2024.103639","article-title":"Human induced pluripotent stem cell line (PNUSCRi005-A) generated from severe type of Hunter syndrome patient carrying exonic deletion (exon 4\u20137 del) in in human iduronate 2-sulfatase gene","volume":"83","author":"Lee","year":"2025","journal-title":"Stem Cell Res."},{"key":"10.1016\/j.yexmp.2026.105079_bb0385","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13023-021-01743-2","article-title":"Natural progression of cardiac features and long-term effects of enzyme replacement therapy in Taiwanese patients with mucopolysaccharidosis II","volume":"16","author":"Lin","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0390","series-title":"Newborn Screening Program for Mucopolysaccharidosis Type II and Long-Term Follow-Up of the Screen-Positive Subjects in Taiwan","author":"Lin","year":"2022"},{"key":"10.1016\/j.yexmp.2026.105079_bb0395","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/s41573-023-00766-7","article-title":"AAV-based in vivo gene therapy for neurological disorders","volume":"22","author":"Ling","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.yexmp.2026.105079_bb0400","article-title":"Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey","volume":"2","author":"Link","year":"2010","journal-title":"Orthop. Rev. (Pavia)"},{"key":"10.1016\/j.yexmp.2026.105079_bb0405","series-title":"Mucopolysaccharidosis Type II in a Female Patient with a Reciprocal X;9 Translocation and Skewed X Chromosome Inactivation","author":"Lonardo","year":"2014"},{"key":"10.1016\/j.yexmp.2026.105079_bb0410","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/humu.20165","article-title":"Characterization of iduronate-2-sulfatase gene-pseudogene recombinations in eight patients with Mucopolysaccharidosis type II revealed by a rapid PCR-based method","volume":"25","author":"Lualdi","year":"2005","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.yexmp.2026.105079_bb0415","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41419-024-06661-2","article-title":"Mucopolysaccharidosis type II zebrafish model exhibits early impaired proteasomal-mediated degradation of the axon guidance receptor Dcc","volume":"15","author":"Manzoli","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0420","doi-asserted-by":"crossref","first-page":"e377","DOI":"10.1542\/peds.2007-1350","article-title":"Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome)","volume":"121","author":"Martin","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.yexmp.2026.105079_bb0425","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1080\/21541264.2016.1264353","article-title":"TFEB and TFE3: the art of multi-tasking under stress conditions","volume":"8","author":"Martina","year":"2017","journal-title":"Transcription"},{"key":"10.1016\/j.yexmp.2026.105079_bb0430","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/mt.2008.171","article-title":"Self-complementary AAV vectors; advances and applications","volume":"16","author":"McCarty","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0435","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1097\/GIM.0b013e3181f6e74d","article-title":"Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): data from the Hunter Outcome Survey","volume":"12","author":"Mendelsohn","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0440","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/j.ymthe.2021.01.027","article-title":"Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice","volume":"29","author":"Morimoto","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0445","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.gene.2016.03.029","article-title":"Cell cycle is disturbed in mucopolysaccharidosis type II fibroblasts, and can be improved by genistein","volume":"585","author":"Moskot","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.yexmp.2026.105079_bb0450","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/adc.58.11.911","article-title":"Hunter\u2019s disease in a girl: association with X:5 chromosomal translocation disrupting the Hunter gene","volume":"58","author":"Mossman","year":"1983","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.yexmp.2026.105079_bb0455","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.86696","article-title":"CNS-directed gene therapy for the treatment of neurologic and somatic mucopolysaccharidosis type II (Hunter syndrome)","volume":"1","author":"Motas","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.yexmp.2026.105079_bb0460","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0465","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/GIM.0b013e3181fea459","article-title":"Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome","volume":"13","author":"Muenzer","year":"2011","journal-title":"Genet. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0470","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","article-title":"A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II","volume":"18","author":"Muenzer","year":"2016","journal-title":"Genet. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0475","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13023-017-0635-z","article-title":"Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry","volume":"12","author":"Muenzer","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0480","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1186\/s13023-021-02052-4","article-title":"Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS)","volume":"16","author":"Muenzer","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0485","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2022.07.017","article-title":"Intrathecal idursulfase-IT in patients with neuronopathic mucopolysaccharidosis II: results from a phase 2\/3 randomized study","volume":"137","author":"Muenzer","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0490","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s13023-023-02805-3","article-title":"Neurodevelopmental status and adaptive behavior of pediatric patients with mucopolysaccharidosis II: a longitudinal observational study","volume":"18","author":"Muenzer","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108535","article-title":"Community consensus for Heparan sulfate as a biomarker to support accelerated approval in neuronopathic mucopolysaccharidoses","volume":"142","author":"Muenzer","year":"2024","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109284","article-title":"Clinical characteristics and real-world outcomes in patients with mucopolysaccharidosis II over 18 years: final report of the Hunter Outcome Survey","volume":"146","author":"Muenzer","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0505","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa2508681","article-title":"An intravenous brain-penetrant enzyme therapy for mucopolysaccharidosis II","volume":"394","author":"Muenzer","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0515","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13023-025-03881-3","article-title":"Challenges and opportunities with providing genetic testing and counseling for mucopolysaccharidosis type II in Kenya","volume":"20","author":"Mungai","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0520","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s40246-023-00522-3","article-title":"The application of long-read sequencing in clinical settings","volume":"17","author":"Oehler","year":"2023","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.yexmp.2026.105079_bb0525","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ymthe.2020.09.039","article-title":"A phase 2\/3 trial of Pabinafusp alfa, IDS fused with anti-human transferrin receptor antibody, targeting neurodegeneration in MPS-II","volume":"29","author":"Okuyama","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0530","series-title":"LCR-Initiated Rearrangements at the IDS Locus, Completed with Alu-Mediated Recombination or Non-Homologous End Joining","author":"Oshima","year":"2011"},{"key":"10.1016\/j.yexmp.2026.105079_bb0535","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13023-015-0265-2","article-title":"Immunogenicity of idursulfase and clinical outcomes in very young patients (16 months to 7.5 years) with mucopolysaccharidosis II (Hunter syndrome)","volume":"10","author":"Pano","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0540","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/jnc.14632","article-title":"The role of innate immunity in mucopolysaccharide diseases","volume":"148","author":"Parker","year":"2019","journal-title":"J. Neurochem."},{"key":"10.1016\/j.yexmp.2026.105079_bb0545","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21103433","article-title":"Evading the AAV immune response in mucopolysaccharidoses","volume":"21","author":"Piechnik","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2026.105079_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2022.151232","article-title":"Changes in expression of signal transduction-related genes, and formation of aggregates of GPER1 and OXTR receptors in mucopolysaccharidosis cells","volume":"101","author":"Pierzynowska","year":"2022","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0555","series-title":"Mucopolysaccharidosis Type II in a Female Carrying a Heterozygous Stop Mutation of the Iduronate-2-Sulfatase Gene and Showing a Skewed X Chromosome Inactivation","author":"Pi\u00f1a-Aguilar","year":"2013"},{"key":"10.1016\/j.yexmp.2026.105079_bb0560","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.ejhg.5201623","article-title":"Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses","volume":"14","author":"Piotrowska","year":"2006","journal-title":"Eur. J. Hum. Genet."},{"key":"10.1016\/j.yexmp.2026.105079_bb0565","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2017.00110","article-title":"Crosstalk between lysosomes and mitochondria in Parkinson\u2019s disease","volume":"5","author":"Plotegher","year":"2017","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0570","series-title":"Mutational Spectrum of the Iduronate-2-Sulfatase Gene in Mexican Patients with Hunter Syndrome","author":"Ram\u00edrez-Hern\u00e1ndez","year":"2022"},{"key":"10.1016\/j.yexmp.2026.105079_bb0575","series-title":"Evidence and Recommendation for Mucopolysaccharidosis Type II Newborn Screening in the United States","author":"Ream","year":"2023"},{"key":"10.1016\/j.yexmp.2026.105079_bb0580","series-title":"REGENXBIO Announces Regulatory Update on RGX-121 for MPS II","author":"REGENXBIOInc","year":"2026"},{"key":"10.1016\/j.yexmp.2026.105079_bb0585","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10545-017-0108-5","article-title":"Neural cells generated from human induced pluripotent stem cells as a model of CNS involvement in mucopolysaccharidosis type II","volume":"41","author":"Rybova","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0590","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18051072","article-title":"Brain RNA-seq profiling of the mucopolysaccharidosis type II mouse model","volume":"18","author":"Salvalaio","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.yexmp.2026.105079_bb0595","series-title":"Endogenous, Non-reducing End Glycosaminoglycan Biomarkers for the Mucopolysaccharidoses: Accurate Diagnosis and Elimination of False Positive Newborn Screening Results","author":"Saville","year":"2023"},{"key":"10.1016\/j.yexmp.2026.105079_bb0600","series-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"2025"},{"key":"10.1016\/j.yexmp.2026.105079_bb0605","series-title":"GeneReviews((R))","article-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"2025"},{"key":"10.1016\/j.yexmp.2026.105079_bb0610","series-title":"GeneReviews((R))","article-title":"Mucopolysaccharidosis Type II","author":"Scarpa","year":"2026"},{"key":"10.1016\/j.yexmp.2026.105079_bb0615","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-6-72","article-title":"Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease","volume":"6","author":"Scarpa","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0620","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12881-019-0807-x","article-title":"Case report: a rare case of Hunter syndrome (type II mucopolysaccharidosis) in a girl","volume":"20","author":"Semyachkina","year":"2019","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.yexmp.2026.105079_bb0625","article-title":"Natural history of cognitive development in neuronopathic mucopolysaccharidosis type II (Hunter syndrome): contribution of genotype to cognitive developmental course","volume":"24","author":"Seo","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107709","article-title":"Intracerebroventricular enzyme replacement therapy in patients with neuronopathic mucopolysaccharidosis type II: final report of 5-year results from a Japanese open-label phase 1\/2 study","volume":"140","author":"Seo","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0635","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1089\/hum.2022.141","article-title":"Phenotypic correction of murine mucopolysaccharidosis type II by engraftment of ex vivo lentiviral vector-transduced hematopoietic stem and progenitor cells","volume":"33","author":"Smith","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2024.101201","article-title":"Comparative dose effectiveness of intravenous and intrathecal AAV9.CB7.hIDS, RGX-121, in mucopolysaccharidosis type II mice","volume":"32","author":"Smith","year":"2024","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.yexmp.2026.105079_bb0645","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4103\/2229-5178.198772","article-title":"Pebbling of skin: cutaneous marker of Hunter syndrome","volume":"8","author":"Srinivas","year":"2017","journal-title":"Indian Dermatol. Online J."},{"key":"10.1016\/j.yexmp.2026.105079_bib789","first-page":"100563","article-title":"Newborn screening for mucopolysaccharidoses: Measurement of glycosaminoglycans by LC-MS\/MS","volume":"22","author":"Stapleton","year":"2020","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.yexmp.2026.105079_bb0650","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2022.1054069","article-title":"Strategies to improve safety profile of AAV vectors","volume":"2","author":"Suoranta","year":"2022","journal-title":"Front. Mol. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0655","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ymgme.2012.09.004","article-title":"Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan","volume":"107","author":"Tanaka","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0660","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2018.07.013","article-title":"Evaluation of cerebrospinal fluid heparan sulfate as a biomarker of neuropathology in a murine model of mucopolysaccharidosis type II using high-sensitivity LC\/MS\/MS","volume":"125","author":"Tanaka","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.yexmp.2026.105079_bb0665","series-title":"Evaluation of Cerebrospinal Fluid Heparan Sulfate as a Biomarker of Neuropathology in a Murine Model of Mucopolysaccharidosis Type II Using High-Sensitivity LC\/MS\/MS","author":"Tanaka","year":"2018"},{"key":"10.1016\/j.yexmp.2026.105079_bb0670","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1136\/jmg.35.8.646","article-title":"Reassessment of biochemically determined Hunter syndrome carrier status by DNA testing","volume":"35","author":"Timms","year":"1998","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.yexmp.2026.105079_bb0675","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1111\/pde.12971","article-title":"Cutaneous manifestations of mucopolysaccharidoses","volume":"33","author":"Tran","year":"2016","journal-title":"Pediatr. Dermatol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0680","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1080\/14740338.2020.1751120","article-title":"Safety and efficacy of idursulfase in the treatment of mucopolysaccharidosis II (Hunter syndrome): a post-marketing study in Japan","volume":"19","author":"Ueda","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.yexmp.2026.105079_bb0685","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3174\/ajnr.A0510","article-title":"Correlation of MR imaging and MR spectroscopy findings with cognitive impairment in mucopolysaccharidosis II","volume":"28","author":"Vedolin","year":"2007","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0690","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9020396","article-title":"Brain pathology in mucopolysaccharidoses (MPS) patients with neurological forms","volume":"9","author":"Viana","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0695","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/dmcn.13467","article-title":"Genotype-phenotype relationship in mucopolysaccharidosis II: predictive power of IDS variants for the neuronopathic phenotype","volume":"59","author":"Vollebregt","year":"2017","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0700","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/jimd.12342","article-title":"Can serial cerebral MRIs predict the neuronopathic phenotype of MPS II?","volume":"44","author":"Vollebregt","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0705","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s10545-012-9563-1","article-title":"Anaesthesia and airway management in mucopolysaccharidosis","volume":"36","author":"Walker","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0710","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0715","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.136080","article-title":"The future of newborn screening for lysosomal disorders","volume":"760","author":"Wasserstein","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.yexmp.2026.105079_bb0720","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.2147\/DDDT.S139601","article-title":"Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future","volume":"11","author":"Whiteman","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.yexmp.2026.105079_bb0725","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.jpeds.2012.11.039","article-title":"Relationship of sleep to pulmonary function in mucopolysaccharidosis II","volume":"162","author":"Wooten","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0730","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.yexmp.2026.105079_bb0735","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13020-020-00402-1","article-title":"Transcription factor EB agonists from natural products for treating human diseases with impaired autophagy-lysosome pathway","volume":"15","author":"Xu","year":"2020","journal-title":"Chin. Med."},{"key":"10.1016\/j.yexmp.2026.105079_bb0740","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1186\/s13023-025-04025-3","article-title":"Allogeneic hematopoietic stem cell transplantation modulates neurodevelopmental trajectories in mucopolysaccharidosis: a longitudinal study of subtype-specific outcomes and age-dependent efficacy","volume":"20","author":"Xu","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.yexmp.2026.105079_bb0745","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1469-8749.1983.tb13794.x","article-title":"The natural history of the severe form of Hunter\u2019s syndrome: a study based on 52 cases","volume":"25","author":"Young","year":"1983","journal-title":"Dev. Med. Child Neurol."},{"issue":"11","key":"10.1016\/j.yexmp.2026.105079_bb0750","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/adc.57.11.828","article-title":"Mild form of Hunter\u2019s syndrome: clinical delineation based on 31 cases","volume":"57","author":"Young","year":"1982","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.yexmp.2026.105079_bb0755","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3174\/ajnr.A2832","article-title":"Brain and spinal MR imaging findings in mucopolysaccharidoses: a review","volume":"34","author":"Zafeiriou","year":"2013","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"10.1016\/j.yexmp.2026.105079_bb0760","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s40259-024-00675-0","article-title":"Targeting neurological aspects of mucopolysaccharidosis type II: enzyme replacement therapy and beyond","volume":"38","author":"Zanetti","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.yexmp.2026.105079_bb0765","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40246-024-00701-w","article-title":"Molecular basis of mucopolysaccharidosis type II (Hunter syndrome): first review and classification of published IDS gene variants","volume":"18","author":"Zanetti","year":"2024","journal-title":"Hum. Genomics"},{"key":"10.1016\/j.yexmp.2026.105079_bb0770","series-title":"Analysis of Glycosaminoglycans in Cerebrospinal Fluid from Patients with Mucopolysaccharidoses by Isotope-Dilution Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry","author":"Zhang","year":"2011"},{"key":"10.1016\/j.yexmp.2026.105079_bb0775","series-title":"Genetic Analysis of 63 Chinese Patients with Mucopolysaccharidosis Type II: Functional Characterization of Seven Novel IDS Variants","author":"Zhang","year":"2019"},{"key":"10.1016\/j.yexmp.2026.105079_bb0780","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13052-025-01919-7","article-title":"Allogeneic hematopoietic stem cell transplantation for mucopolysaccharidosis patients: a single-center experience and assessment of quality of life","volume":"51","author":"Zhang","year":"2025","journal-title":"Ital. J. Pediatr."}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480026000584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480026000584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T14:22:03Z","timestamp":1793024523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480026000584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":161,"alternative-id":["S0014480026000584"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105079","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hunter syndrome (mucopolysaccharidosis type II): Molecular mechanisms, CNS biomarkers, and emerging therapeutic strategies","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2026.105079","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"105079"}}